Insulin-Like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBP-1, -2 and -3) in Diabetic Pregnancy: Relationship to Macrosomia.

Liu, Yanjun; Tsushima, Takahiro; Minei, Satomi; Sanaka, Mayumi; Nagashima, Tamaki; Yanagisawa, Keiji; Omori, Yasue

doi:10.1507/endocrj.43.221

Cited by 27 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have shown that concentrations of IGF-I and IGF-II in the cord blood of the newborns of diabetic mothers are higher than in infants born to normal mothers [4]. Furthermore, there was a positive correlation between the cord IGF-I or IGF-II level and birth weight of newborns, suggesting that both IGF-I and IGF-II are involved in fetal growth, but the role of IGFs and their binding proteins produced in placental tissues in regulating human fetal or placental growth is unknown.…”

mentioning

confidence: 86%

See 1 more Smart Citation

Expression of Messenger RNA of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins (IGFBP1-6) in Placenta of Normal and Diabetic Pregnancy.

Liu¹,

Tsushima

Onoda

et al. 1996

Endocr J

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 86%

“…RNAs of IGF-I, IGF-II and all species of IGFBPs (IGFBP- [1][2][3][4][5][6] were expressed in human placenta.…”

Section: Messengermentioning

confidence: 99%

Expression of Messenger RNA of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins (IGFBP1-6) in Placenta of Normal and Diabetic Pregnancy.

Liu¹,

Tsushima

Onoda

et al. 1996

Endocr J

Self Cite

View full text Add to dashboard Cite

“…Several studies investigated the associations of IGF-I and IGFBPs in maternal plasma in pregnancies complicated with DM. Maternal IGF-I was decreased in diabetic pregnancies [95], whereas fetal IGF1 serum levels were increased in infants of mothers with T1DM and T2DM compared to non-diabetic controls [96]. Higher levels of IGFBP3 were observed in both maternal and fetal serum in T1DM pregnancies compared to non-diabetic controls, probably due to increased proteolysis in maternal but not in fetal serum [93].…”

Section: Human Placental Growth Hormone (Pgh)-igf Axis and Fetal Growthmentioning

confidence: 99%

Diabetes during Pregnancy: A Maternal Disease Complicating the Course of Pregnancy with Long-Term Deleterious Effects on the Offspring. A Clinical Review

Ornoy

Becker

Weinstein-Fudim³

et al. 2021

IJMS

178

101

View full text Add to dashboard Cite

In spite of the huge progress in the treatment of diabetes mellitus, we are still in the situation that both pregestational (PGDM) and gestational diabetes (GDM) impose an additional risk to the embryo, fetus, and course of pregnancy. PGDM may increase the rate of congenital malformations, especially cardiac, nervous system, musculoskeletal system, and limbs. PGDM may interfere with fetal growth, often causing macrosomia, but in the presence of severe maternal complications, especially nephropathy, it may inhibit fetal growth. PGDM may also induce a variety of perinatal complications such as stillbirth and perinatal death, cardiomyopathy, respiratory morbidity, and perinatal asphyxia. GDM that generally develops in the second half of pregnancy induces similar but generally less severe complications. Their severity is higher with earlier onset of GDM and inversely correlated with the degree of glycemic control. Early initiation of GDM might even cause some increase in the rate of congenital malformations. Both PGDM and GDM may cause various motor and behavioral neurodevelopmental problems, including an increased incidence of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Most complications are reduced in incidence and severity with the improvement in diabetic control. Mechanisms of diabetic-induced damage in pregnancy are related to maternal and fetal hyperglycemia, enhanced oxidative stress, epigenetic changes, and other, less defined, pathogenic mechanisms.

show abstract

“…However, cord serum IGFBP-1 measure-ments have yielded inconsistent results in diabetic pregnancies, i.e. both low [14] and high [15] levels have been found, with no association with birth weight. These studies relied on assays with unknown specificities for the different IGFBP-1 phosphoisoforms.…”

Section: Introductionmentioning

confidence: 99%

Effect of maternal diabetes on phosphorylation of insulin‐like growth factor binding protein‐1 in cord serum

et al. 2005

View full text Add to dashboard Cite

Maternal diabetes is associated with suppressed hpIGFBP-1 but unaltered lpIGFBP-1 concentrations in cord serum, suggesting that IGFBP-1 phosphoisoforms are differentially regulated in the fetus. Because hpIGFBP-1 has a higher affinity for IGF-I than does lpIGFBP-1, diabetes-related changes in fetal IGFBP-1 phosphorylation may increase IGF-I bioavailability and, consequently, stimulate fetal growth. This may partly explain the increased occurrence of macrosomia in diabetic pregnancies.

show abstract

Insulin-Like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBP-1, -2 and -3) in Diabetic Pregnancy: Relationship to Macrosomia.

Cited by 27 publications

References 42 publications

Expression of Messenger RNA of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins (IGFBP1-6) in Placenta of Normal and Diabetic Pregnancy.

Expression of Messenger RNA of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins (IGFBP1-6) in Placenta of Normal and Diabetic Pregnancy.

Diabetes during Pregnancy: A Maternal Disease Complicating the Course of Pregnancy with Long-Term Deleterious Effects on the Offspring. A Clinical Review

Effect of maternal diabetes on phosphorylation of insulin‐like growth factor binding protein‐1 in cord serum

Contact Info

Product

Resources

About